Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications

Expert Review of Clinical Pharmacology

Volumn 10, Issue 4, 2017, Pages 409-428

  Hamed, Sherifa A ^a  

^a ASSIUT UNIVERSITY   (Egypt)

Author keywords

brain injury; cognition; diabetic ketoacidosis; hippocampus; hypoglycemia; long term potentiation; neuroprotection; neurorestoration; Type 1 diabetes mellitus; type 2 diabetes mellitus

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CHOLINE ACETYLTRANSFERASE; GLUCOSE; GLUTAMATE RECEPTOR; INSULIN; INSULIN RECEPTOR; NEUROPROTECTIVE AGENT; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; TAU PROTEIN; ANTIDIABETIC AGENT;

APOPTOSIS; BRAIN INJURY; CELL THERAPY; COGNITIVE DEFECT; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPOGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NEUROPROTECTION; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; REVIEW; VASCULAR DISEASE; ANIMAL; BRAIN INJURIES; COGNITION DISORDERS; COMPLICATION; DRUG DESIGN; PATHOPHYSIOLOGY;

ANIMALS; BRAIN INJURIES; COGNITION DISORDERS; DIABETES MELLITUS; DRUG DESIGN; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; NEUROPROTECTIVE AGENTS;

EID: 85015851906     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2017.1293521     Document Type: Review

References (258)

1. American Diabetes Association (ADA). Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(Suppl. 1):S11–S66.
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes:estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053.
3. Patterson C, Guariguata L, Dahlquist G, et al. Diabetes in the young - a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res Clin Pract. 2014;103(2):161–175.
4. International Diabetes Federation. The IDF Diabetes Atlas. 5th. Brussels:International Diabetes Federation; 2011. Available from:http://www.idf.org/idf-diabetes-atlas-fifth-edition
5. Sharma M, Petersen I, Nazareth I, et al. An alogorism for identification and classification of individuals with type 1 and type 2 diabetes mellitus in a large primary care database. Clin Epidemiol. 2016;8:373–380.
6. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, Jacobson AM, Musen G, Ryan CM, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007;356(18):1842–1852.
7. Kodl CT, Franc DT, Rao JP, et al. Diffusion tensor imaging identifies deficits in white matter microstructure in subjects with type 1 diabetes that correlate with reduced neurocognitive function. Diabetes. 2008;57(11):3083–3089.
8. Kaufman FR, Epport K, Engilman R, et al. Neurocognitive functioning in children diagnosed with diabetes before age 10 years. J Diabetes Complications. 1999;13(1):31–38.
9. Ryan CM, Geckle MO, Orchard TJ., Cognitive efficiency declines over time in adults with type 1 diabetes:effects of micro- and macrovascular complications. Diabetologia. 2003;46(7):940–948.
10. Cox DJ, Kovatchev BP, Gonder-Frederick LA, et al. Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care. 2005;28(1):71–77.
11. Den Heijer T, Launer LJ, Prins ND, et al. Type 2 diabetes and atrophy of the medial temporal lobe structures. Diabetologia. 2003;46(12):1604–1610.
12. Mohamadi Y, Jameie SB, Akbari M, et al. Hyperglycemia decreased medial amygdala projections to medial preoptic area in experimental model of diabetes mellitus. Acta Med Iran. 2015;53(1):1–7.
13. Vincent C, Hall PA. Executive function in adults with type 2 diabetes:a meta-analytic review. Psychosom Med. 2015;77(6):631–642.
14. Moran C, Beare R, Phan TG, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI). Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology. 2015;85(13):1123–1130.
15. Sadeghi A, Hami J, Razavi S, et al. The effect of diabetes mellitus on apoptosis in hippocampus:cellular and molecular aspects. Int J Prev Med. 2016;7:57.
16. Strachan MW, Reynolds RM, Frier BM, et al. The role of metabolic derangements and glucocorticoid excess in the aetiology of cognitive impairment in type 2 diabetes. Implications for future therapeutic strategies. Diabetes Obes Metab. 2009;11(5):407–414.
17. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment:insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.
18. Folstein MF, Folstein SE, McHugh PH. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.
19. Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance. Neurology. 1999;52(5):971–975.
20. Kuusisto J, Koivisto K, Mykkanen L, et al. Association between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein E4 phenotype:cross-sectional population based study. BMJ. 1997;315(7115):1045–1049.
21. Kanaya AM, Barrett-Connor E, Gildengorin G, et al. Change in cognitive function by glucose tolerance status in older adults:A 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med. 2004;164(12):1327–1333.
22. Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med. 2013;369(6):540–548.
23. Ferguson SC, Blane A, Perros P, et al. Cognitive ability and brain structure in type 1 diabetes:relation to microangiopathy and preceding severe hypoglycemia. Diabetes. 2003;52(1):149–156.
24. Siqueira LF. Cerebrovascular complications of diabetic ketoacidosis in children. Arq Bras Endocrinol Metabol. 2011;55(4):288–290.
25. Bekyarova GY, Ivanova DG, Madjova VH. Molecular mechanisms associating oxidative stress with endothelial dysfunction in the development of various vascular complications in diabetes mellitus. Folia Med (Plovdiv). 2007;49(3–4):13–19.•• Presentation of the evidence and possible mechanisms of diabetes-induced complications.
26. Fishel MA, Watson GS, Montine TJ, et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol. 2005;62(10):1539–1544.
27. Wang T, Fu F, Han B, et al. Danshensu ameliorates the cognitive decline in streptozotocin-induced diabetic mice by attenuating advanced glycation end product-mediated neuroinflammation. J Neuroimmunol. 2012;245(1–2):79–86.
28. Zhou X, Zhang F, Hu X, et al. Inhibition of inflammation by astaxanthin alleviates cognition deficits in diabetic mice. Physiol Behav. 2015;151:412–420.
29. Xu L, Zhu J, Yin W, et al. Astaxanthin improves cognitive deficits from oxidative stress, nitric oxide synthase and inflammation through upregulation of PI3K/Akt in diabetes rat. Int J Clin Exp Pathol. 2015;8(6):6083–6094.
30. Li ZG, Zhang W, Sima AA. C-peptide prevents hippocampal apoptosis in type 1 diabetes. Int J Exp Diabetes Res. 2002;3(4):241–245.
31. Jafari Anarkooli I, Sankian M, Ahmadpour S, et al. Evaluation of Bcl-2 family gene expression and Caspase-3 activity in hippocampus STZ-induced diabetic rats. Exp Diabetes Res. 2008;2008:638467.
32. Zhang T, Jia W, Sun X. 3-n-butylphthalide (NBP) reduces apoptosis and enhances vascular endothelial growth factor (VEGF) up-regulation in diabetic rats. Neurol Res. 2010;32(4):390–396.
33. Chen Y, Li L, Li Z, et al. Effects of naokang erhao decoction on cognitive ability and hippocampal apoptosis-related proteins in diabetic rats. Zhongguo Zhong Yao Za Zhi. 2011;36(11):1519–1523.
34. Zhao CH, Liu HQ, Cao R, et al. Effects of dietary fish oil on learning function and apoptosis of hippocampal pyramidal neurons in streptozotocin-diabetic rats. Brain Res. 2012;1457:33–43.
35. Sun LJ, Hou XH, Xue SH, et al. Oil modulates glycogen synthase kinase-3 signaling pathway in diabetes-induced hippocampal neurons apoptosis. Brain Res. 2014;1574:37–49.
36. Yonguc GN, Dodurga Y, Adiguzel E, et al. Grape seed extract has superior beneficial effects than Vitamin E on oxidative stress and apoptosis in the hippocampus of streptozotocin induced diabetic rats. Gene. 2015;555(2):119–126.
37. Yan T, Venkat P, Ye X, et al. HUCBCs increase angiopoietin 1 and induce neurorestorative effects after stroke in T1DM rats. CNS Neurosci Ther. 2014;20(10):935–944.
38. Yan T, Venkat P, Chopp M, et al. Neurorestorative therapy of stroke in type 2 diabetes mellitus rats treated with human umbilical cord blood cells. Stroke. 2015;46(9):2599–2606.
39. Zhang L, Chopp M, Zhang Y, et al. Diabetes mellitus impairs cognitive function in middle-aged rats and neurological recovery in middle-aged rats after stroke. Stroke. 2016;47(8):2112–2118.
40. Nakano M, Nagaishi K, Konari N, et al. Bone marrow-derived mesenchymal stem cells improve diabetes-induced cognitive impairment by exosome transfer into damaged neurons and astrocytes. Sci Rep. 2016;6:24805.
41. Sünram-Lea SI, Foster JK, Durlach P, et al. Glucose facilitation of cognitive performance in healthy young adults:examination of the influence of fast-duration, time of day and pre-consumption plasma glucose levels. Psychopharmacology. 2001;157(1):46–54.
42. Hoyland A, Dye L, Lawton CL. A systematic review of the effect of breakfast on the cognitive performance of children and adolescents. Nutr Res Rev. 2009;22(2):220–243.
43. Singh P, Jain A, Kaur G. Impact of hypoglycemia and diabetes on CNS:correlation of mitochondrial oxidative stress with DNA damage. Mol Cell Biochem. 2004;260(1–2):153–159.
44. Perantie DC, Wu J, Koller JM, et al. Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. Diabetes Care. 2007;30(9):2331–2337.
45. Cameron FJ, Scratch SE, Nadebaum C, et al. Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. Diabetes Care. 2014;37(6):1554–1562.
46. Cato MA, Mauras N, Mazaika P, et al. Diabetes research in children network. Longitudinal evaluation of cognitive functioning in young children with type 1 diabetes over 18 months. J Int Neuropsychol Soc. 2016;22(3):293–302.
47. Galassetti P, Davis SN. Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycaemia. Clin Sci (Lond). 2000;99(5):351–362.
48. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553.
49. Widom B, Simonson DC. Glycemic control and neuropsychologic function during hypoglycemia in patients with insulin-dependent diabetes mellitus. Ann Intern Med. 1990;112(2):904–912.
50. Won SJ, Yoo BH, Kauppinen TM, et al. Recurrent/moderate hypoglycemia induces hippocampal dendritic injury, microglial activation, and cognitive impairment in diabetic rats. J Neuroinflammation. 2012;9:182.
51. Stollery B, Christian L. Glucose improves object-location binding in visual-spatial working memory. Psychopharmacology (Berl). 2016;233(3):529–547.
52. Fernandez AM, Torres-Alem_an I. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci. 2012;13(4):225–239.
53. Wozniak M, Rydzewski B, Baker P, et al. The cellular and physiological actions of insulin in the central nervous system. Neurochem Int. 1993;22(1):1–40.
54. Ghasemi R, Haeri A, Dargahi L, et al. Insulin in the brain:sources, localization and functions. Mol Neurobiol. 2013;47(1):145–171.
55. Freude S, Plum L, Schnitker J, et al. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes. 2005;54(12):3343–3348.
56. Clarke DW, Mudd L, Boyd FT, et al. Insulin is released from rat brain neuronal cells in culture. J Neurochem. 1986;47(3):831–836.
57. Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol. 2001;177(1–2):125–134.
58. Revsin Y, Rekers NV, Louwe MC, et al. Glucocorticoid receptor blockade normalizes hippocampal alterations and cognitive impairment in streptozotocin-induced type 1 diabetes mice. Neuropsychopharmacol. 2009;34(3):747–758.
59. Segovia G, Porras A, Del Arco A, et al. Glutamatergic neurotransmission in aging:a critical perspective. Mech Ageing Dev. 2001;122(1):1–29.
60. Alspac Study, Team, Gunnell D, Miller LL, Rogers I, et al. Association of insulin-like growth factor I and insulin-like growth factor-binding protein-3 with intelligence quotient among 8- to 9-year-old children in the Avon Longitudinal Study of Parents and Children. Pediatrics. 2005;116(5):e681–686.
61. Garcia-Segura LM, Rodriguez JR, Torres-Aleman I. Localization of the insulin-like growth factor I receptor in the cerebellum and hypothalamus of adult rats:an electron microscopic study. J Neurocytol. 1997;26(7):479–490.
62. Van Der Heide LP, Ramakers GM, Smidt MP. Insulin signaling in the central nervous system:learning to survive. Prog Neurobiol. 2006;79(4):205–221.
63. Zhu X, Raina AK, Lee HG, et al. Oxidative stress and neuronal adaptation in Alzheimer disease:the role of SAPK pathways. Antioxid Redox Signal. 2003;5(5):571–576.
64. Lee -C-C, Huang -C-C, Hsu K-S. Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways. Neuropharmacology. 2011;61(4):867–879.
65. Recio-Pinto E, Rechler MM, Ishii DN. Effects of insulin, insulin-like growth factor-II, and nerve growth factor on neurite formation and survival cultured sympathetic and sensory neurons. J Neurosci. 1986;6(5):1211–1219.
66. Izquierdo I, Bevilaqua LRM, Rossato JI, et al. Different molecular cascades in different sites of the brain control memory consolidation. Trends Neurosci. 2006;29(9):496–505.•• Presentation of the mechanisms of memory consolidation.
67. Chiu S, Chen C, Cline H. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function In Vivo. Neuron. 2008;58(5):708–719.
68. McNay EC, Recknagel AK. Brain insulin signaling:a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol Learn Mem. 2011;96(3):432–442.
69. Kamal A, Biessels GJ, Urban IJ, et al. Hippocampal synaptic plasticity in streptozotocin-diabetic rats:impairment of long-term potentiation and facilitation of long-term depression. Neuroscience. 1999;90(3):737–745.
70. Manning CA, Ragozzino ME, Gold PE. Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer’s type. Neurobiol Aging. 1993;14(6):523–528.
71. Bingham EM, Hopkins D, Smith D, et al. The role of insulin in human brain glucose metabolism:an 18fluoro-deoxyglucose positron emission tomography study. Diabetes. 2002;51(12):3384–3390.
72. Boyd FT, Jr, Clarke DW, Muther TF, et al. Insulin receptors and insulin modulation of norepinephrine uptake in neuronal cultures from rat brain. J Biol Chem. 1985;260(29):15880–15884.
73. Van Der Heide LP, Kamal A, Artola A, et al. Insulin modulates hippocampal activity-dependent synaptic plasticity in a N-methyl-D-aspartate receptor and phosphatidyl-inositol-3-kinase-dependent manner. J Neurochem. 2005;94(4):1158–1166.
74. Duarte AI, Santos MS, Seiça R, et al. Insulin affects synaptosomal GABA and glutamate transport under oxidative stress conditions. Brain Res. 2003;977(1):23–30.
75. Flood JF, Mooradian AD, Morley JE. Characteristics of learning and memory in streptozocin-induced diabetic mice. Diabetes. 1990;39(11):1391–1398.
76. Popoviç M, Biessels GJ, Isaacson RL, et al. Learning and memory in streptozotocin-induced diabetic rats in a novel spatialobject discrimination task. Behav Brain Res. 2001;122(2):201–207.
77. Mordes JP, Bortell R, Blankenhorn EP, et al. Rat models of type 1 diabetes:genetics, environment, and autoimmunity. Ilar J. 2004;45(3):278–291.
78. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–432.
79. Shafrir E. Diabetes in animals:Contribution to the understanding of diabetes by study of its etiopathology in animal models. In:Porte D. Sherwin RS, Baron A, editors. Diabetes mellitus. New York:McGraw-Hill; 2003. p. 213–255.
80. Lindstrom P. The physiology of obese-hyperglycemic mice [ob/ob mice]. Scientific World Journal. 2007;7:666–685.
81. Chehab FF, Lim ME, Lu R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet. 1996;12(3):318–320.
82. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor:identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996;84(3):491–495.
83. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research:an overview. Indian J Med Res. 2007;125(3):451–472.
84. Phillips MS, Liu Q, Hammond HA, et al. Leptin receptor missense mutation in the fatty Zucker rat. Nat Genet. 1996;13(1):18–19.
85. Pick A, Clark J, Kubstrup C, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes. 1998;47(3):358–364.
86. Sandler S, Swenne I. DNA repair synthesis in the pancreatic islets of streptozotocin-treated mice. Diabetes Res. 1985;2(5):255–258.
87. Dufrane D, Van Steenberghe M, Guiot Y, et al. Streptozotocin-induced diabetes in large animals (pigs/primates):role of GLUT2 transporter and beta-cell plasticity. Transplantation. 2006;81(1):36–45.
88. Shibata T, Takeuchi S, Yokota S, et al. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol. 2000;130(3):495–504.
89. Biessels GJ, Kamal A, Urban IJ, et al. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats:effects of insulin treatment. Brain Res. 1998;800(1):125–135.
90. Kuhad A, Bishnoi M, Tiwari V, et al. Suppression of NF-kappabeta signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Pharmacol Biochem Behav. 2009;92(2):251–259.
91. Wang T, Fu FH, Han B, et al. Long-term but not short-term aspirin treatment attenuates diabetes-associated learning and memory decline in mice. Exp Clin Endocrinol Diabetes. 2011;119(1):36–40.
92. Moghadamnia AA, Hakiminia S, Baradaran M, et al. Vitamin D improves learning and memory impairment in streptozotocin-induced diabetic mice. Arch Iran Med. 2015;18(6):362–366.
93. Jafari Anarkooli I, Barzegar Ganji H, Pourheidar M. The protective effects of insulin and natural honey against hippocampal cell death in streptozotocin-induced diabetic rats. J Diabetes Res. 2014;2014:491571.
94. Wootton-Gorges SL, Buonocore MH, Caltagirone RA, et al. Progressive decrease in N-acetylaspartate/Creatine ratio in a teenager with type 1 diabetes and repeated episodes of ketoacidosis without clinically apparent cerebral edema:evidence for permanent brain injury. AJNR Am J Neuroradiol. 2010;31(4):780–781.•• Presentation of the evidence of structural and functional brain injury with diabetic ketoacidosis.
95. Cosar M, Songur A, Sahin O, et al. The neuroprotective effect of fish n-3 fatty acids in the hippocampus of diabetic rats. Nutr Neurosci. 2008;11(4):161–166.
96. Bruce DG, Casey GP, Grange V, et al. Cognitive impairment, physical disability and depressive symptoms in older diabetic patients:the Fremantle Cognition in Diabetes Study. Diabetes Res Clin Pract. 2003;61(1):59–67.
97. Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Investigators, Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors:the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care. 2009;32(2):221–226.
98. Kent S, Chen R, Kumar A, et al. Individual growth curve modeling of specific risk factors and memory in youth with type 1 diabetes:an accelerated longitudinal design. Child Neuropsychol. 2010;16(2):169–181.
99. Mooradian AD, Perryman K, Fitten J, et al. Cortical function in elderly non-insulin dependent diabetic patients:behavioral and electrophysiological studies. Arch Intern Med. 1988;148(11):2369–2372.
100. Pozzessere G, Valle E, De Crignis S, et al. Abnormalities of cognitive functions in IDDM revealed by P300 event related potential analysis. Comparison with short-latency evoked potentials and psychometric tests. Diabetes. 1991;40(8):952–958.
101. Hamed SA, Abd Elaal RF, Mohamad KA, et al. Neuropsychological, neurophysiological and laboratory markers of direct brain injury in type 2 diabetes mellitus. J Neurol Neurosci. 2012;3:2.
102. Pozzessere G, Rizzo PA, Valle E, et al. Early detection of neurological involvement in IDDM and NIDDM. Multimodal evoked potentials versus metabolic control. Diabetes Care. 1988;11(6):473–480.
103. Gupta PR, Dorfman LJ. Spinal somatosensory conduction in diabetes. Neurology. 1981;31((7)1):841–845.
104. Comi G. Evoked potentials in diabetes mellitus. Clin Neurosci. 1997;4(6):374–379.
105. Patiño-Fernández AM, Delamater AM, Applegate EB, et al. Neurocognitive functioning in preschool-age children with type 1 diabetes mellitus. Pediatr Diabetes. 2010;11(6):424–430.
106. Meo SA, Alkahlan MA, Al-Mubarak MA, et al. Impact of type 1 diabetes mellitus on academic performance. J Int Med Res. 2013;41(3):855–858.
107. Northam EA, Anderson PJ, Jacobs R, et al. Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. Diabetes Care. 2001;24(9):1541–1546.
108. Musen G, Lyoo IK, Sparks CR, et al. Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes. 2006;55(2):326–333.
109. Ho MS, Weller NJ, Ives FJ, et al. Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. J Pediatr. 2008;153(3):385–390.
110. Toprak H, Yetis H, Alkan A, et al. Relationships of DTI findings with neurocognitive dysfunction in children with Type 1 diabetes mellitus. Br J Radiol. 2016;89(1059):20150680.
111. Glaser N, Ngo C, Anderson S, et al. Effects of hyperglycemia and effects of ketosis on cerebral perfusion, cerebral water distribution, and cerebral metabolism. Diabetes. 2012;61(7):1831–1837.•• Presentation of the evidence of structural and functional brain injury with diabetic ketoacidosis.
112. Brands AM, Kessels RP, Hoogma RP, et al. Cognitive performance, psychological well-being, and brain magnetic resonance imaging in older patients with type 1 diabetes. Diabetes. 2006;55(6):1800–1806.•• Presentation of the evidence of structural and functional brain injury with type 1 diabetes.
113. Nunley KA, Rosano C, Ryan CM, et al. Clinically relevant cognitive impairment in middle-aged adults with childhood-onset type 1 diabetes. Diabetes Care. 2015;38(9):1768–1776.
114. Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol. 2004;26(8):1044–1080.
115. Strachan MW, Deary IJ, Ewing FM, et al. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care. 1997;20(3):438–445.
116. West RK, Ravona-Springer R, Schmeidler J, et al. The association of duration of type 2 diabetes with cognitive performance is modulated by long-term glycemic control. Am J Geriatr Psychiatry. 2014;22(10):1055–1059.
117. Yaffe K, Blackwell T, Whitmer RA, et al. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging. 2006;10(4):293–295.
118. Khaĭrullin I, Esin RG, Pozdniak AO. Cognitive impairment in patients with diabetes mellitus type 2 and possibilities of its treatment. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(9):25–29.
119. Kawamura T, Umemura T, Hotta N. Cognitive impairment in diabetic patients:can diabetic control prevent cognitive decline? J Diabetes Investig. 2012;3(5):413–423.
120. Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes:a lifespan perspective. Lancet Neurol. 2008;7(2):184–190.
121. Herrmann M, Ehrenreich H. Brain derived proteins as markers of acute stroke:their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor Neurol Neurosci. 2003;21(3–4):177–190.
122. Guzel A, Er U, Tatli M, et al. Serum neuron-specific enolase as a predictor of short-term outcome and its correlation with glasgow coma scale in traumatic brain injury. Neurosurg Rev. 2008;31(4):439–444.
123. Hamed SA, Eltayeb AA, Mohamad HO, et al. Brain function in children with uncomplicated epilepsy:relationship to biomarkers of brain damage (neuron specific enolase and S100β protein). J Pediatric Epilepsy. 2013;2:115–124.
124. Sandhu HS, Butt AN, Powrie J, et al. Measurement of circulating neuron-specific enolase mRNA in diabetes mellitus. Ann N Y Acad Sci. 2008;1137:258–263.
125. Li J, Yan M, Zhang Y, et al. Serum neuron-specific enolase is elevated as a novel indicator of diabetic retinopathy including macular oedema. Diabet Med. 2015;32(1):102–107.
126. Hak AE, Pols HA, Stehouwer CD, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly:the Rotterdam study. J Clin Endocrinol Metab. 2001;86(9):4398–4405.
127. Akisaki T, Sakurai T, Takata T, et al. Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab Res Rev. 2006;22(5):376–384.
128. Moran C, Phan TG, Chen J, et al. Brain atrophy in type 2 diabetes:regional distribution and influence on cognition. Diabetes Care. 2013;36(12):4036–4042.•• Presentation of the evidence of structural brain damage with type 2 diabetes.
129. García-Casares N, Berthier ML, Jorge RE, et al. Structural and functional brain changes in middle-aged type 2 diabetic patients:a cross-sectional study. J Alzheimers Dis. 2014;40(2):375–386.
130. Huang RR, Jia BH, Xie L, et al. Spatial working memory impairment in primary onset middle-age type 2 diabetes mellitus:an ethology and BOLD-fMRI study. J Magn Reson Imaging. 2016;43(1):75–87.
131. Niwa H, Koumoto C, Shiga T, et al. Clinical analysis of cognitive function in diabetic patients by MMSE and SPECT. Diabetes Res Clin Pract. 2006;72(2):142–147.
132. Santhakumari R, Reddy IY, Archana R. Effect of type 2 diabetes mellitus on brain metabolites by using proton magnetic resonance spectroscopy- a systematic review. Int J Pharma Bio Sci. 2014;5(4):1118–1123.
133. Ghetti S, Lee JK, Sims CE, et al. Diabetic ketoacidosis and memory dysfunction in children with type 1 diabetes. J Pediatr. 2010;156(1):109–114.
134. Nett ST, Noble JA, Levin DL, et al. Biomarkers and genetics of brain injury risk in diabetic ketoacidosis:A pilot study. J Pediatr Intensive Care. 2014;3:2.
135. Albuerne M, Mammola CL, Naves FJ, et al. Immunohistochemical localization of S100 proteins in dorsal root, sympathetic and enteric ganglia of several mammalian species, including man. J Peripher Nerv Syst. 1998;3(4):243–253.
136. Hamed S, Metwally KA, Farghaly HS, et al. Serum levels of neuron-specific enolase in children with diabetic ketoacidosis. J Child Neurol. 2017. DOI:10.1177/0883073816686718
137. Blasetti A, Chiuri RM, Tocco AM, et al. The effect of recurrent severe hypoglycemia on cognitive performance in children with type 1 diabetes:a meta-analysis. J Child Neurol. 2011;26(11):1383–1391.
138. Hershey T, Bhargava N, Sadler M, et al. Conventional versus intensive diabetes therapy in children with type 1 diabetes:effects on memory and motor speed. Diabetes Care. 1999;22(8):1318–1324.
139. Wright RJ, Frier BM, Deary IJ. Effects of acute insulin-induced hypoglycemia on spatial abilities in adults with type 1 diabetes. Diabetes Care. 2009;32(8):1503–1506.
140. Warren RE, Zammitt NN, Deary IJ, et al. The effects of acute hypoglycaemia on memory acquisition and recall and prospective memory in type 1 diabetes. Diabetologia. 2007;50(1):178–185.
141. Haumont D, Dorchy H, Pelc S. EEG abnormalities in diabetic children:influence of hypoglycemia and vascular complications. Clin Pediatr (Phila). 1979;18(12):750–753.
142. Reddy GK. Age-related cross-linking of collagen is associated with aortic wall matrix stiffness in the pathogenesis of drug-induced diabetes in rats. Microvasc Res. 2004;68:132–142.
143. Idris I, Thomson GA, Sharma JC. Diabetes mellitus and stroke. Int J Clin Pract. 2006;60(1):48–56.
144. Agabiti-Rosei E, Muiesan ML. Carotid atherosclerosis, arterial stiffness and stroke events. Adv Cardiol. 2007;44:173–186.
145. Ergul A, Elgebaly MM, Middlemore ML, et al. Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol. 2007;7:33.
146. Callahan A, Amarenco P, Goldstein LB, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome:secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (sparcl) trial. Arch Neurol. 2011;68(10):1245–1251.
147. Reske-Nielsen E, Lundbaek K. Pathological changes in the central and peripheral nervous system of young long-term diabetics. II. The spinal cord and peripheral nerves. Diabetologia. 1968;4(1):34–43.
148. Johnson PC, Brendel K, Meezan E. Thickened cerebral cortical capillary basement membranes in diabetics. Arch Pathol Lab Med. 1982;106(5):214–217.
149. SMART-MR Study Group, Kooistra M, Geerlings MI, Mali WP, et al. Diabetes mellitus and progression of vascular brain lesions and brain atrophy in patients with symptomatic atherosclerotic disease. The SMART-MR study. J Neurol Sci. 2013;332(1–2):69–74.
150. Mehrabian S, Raycheva M, Gateva A, et al. Cognitive dysfunction profile and arterial stiffness in type 2 diabetes. J Neurol Sci. 2012;322(1–2):152–156.
151. Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke:a vascular perspective. J Cereb Blood Flow Metab. 2007;27(3):435–451.
152. Cui X, Chopp M, Zacharek A, et al. Angiopoietin/Tie2 pathway mediates type 2 diabetes induced vascular damage after cerebral stroke. Neurobiol Dis. 2011;43(1):285–292.
153. Li W, Qu Z, Prakash R, et al. Comparative analysis of the neurovascular injury and functional outcomes in experimental stroke models in diabetic Goto-Kakizaki rats. Brain Res. 2013;1541:106–114.
154. Ding G, Yan T, Chen J, et al. Persistent cerebrovascular damage after stroke in type two diabetic rats measured by magnetic resonance imaging. Stroke. 2015;46(2):507–512.
155. Deng W, Lu H, Teng J. Carvacrol attenuates diabetes-associated cognitive deficits in rats. J Mol Neurosci. 2013;51(3):813–819.
156. Van Dam PS, Van Asbeck BS, Erkelens DW, et al. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev. 1995;11(3):181–192.
157. El-Kossi AE, Abdellah MM, Rashad AM, et al. The effectiveness of evening primrose in glycemic control and improvement of nerve structure and function in diabetic rats. J Clin Exper Invest. 2011;2(2):133–150.
158. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–445.
159. Christen Y, Maixent JM. What is Ginkgo biloba extract EGb 761? An overview–from molecular biology to clinical medicine. Cell Mol Biol (Noisy-Le-Grand). 2002;48(6):601–611.
160. De Vincenzi M, Stammati A, De Vincenzi A, et al. Constituents of aromatic plants:carvacrol. Fitoterapia. 2004;75(7–8):801–804.
161. Özkan A, Erdoğan A. A comparative evaluation of antioxidant and anticancer activity of essential oil from Origanum onites (Lamiaceae) and its two major phenolic components. Tübitak. 2010;35(2011):735–742.
162. Choi S, Koo S. Efficient syntheses of the keto-carotenoids canthaxanthin, astaxanthin, and astacene. Org Chem. 2005;70(8):3328–3331.
163. Hashimoto M, Shahdat HM, Yamashita S, et al. Docosahexaenoic acid disrupts in vitro amyloid beta(1–40) fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer’s disease model rats. J Neurochem. 2008;107(6):1634–1646.
164. Kapoor L. Handbook of Ayurvedic medicinal plants. Boca Raton, Fla, USA:CRC Press; 1990.
165. Mook-Jung I, Shin JE, Yun SH, et al. Protective effects of asiaticoside derivatives against beta-amyloid neurotoxicity. J Neurosci Res. 1999;58(3):417–425.
166. Hossain S, Hashimoto M, Katakura M, et al. Medicinal value of asiaticoside for Alzheimer’s disease as assessed using single-molecule-detection fluorescence correlation spectroscopy, laser-scanning microscopy, transmission electron microscopy, and in silico docking. BMC Complement Altern Med. 2015;15:118.
167. Scaife MA, Ma CA, Ninlayarn T, et al. Comparative analysis of β-carotene hydroxylase genes for astaxanthin biosynthesis. J Nat Prod. 2012;75(6):1117–1124.
168. Fassett RG, Coombes JS. Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiol. 2009;4(3):333–342.
169. Ursoniu S, Sahebkar A, Serban MC, et al. Lipid profile and glucose changes after supplementation with astaxanthin:a systematic review and meta-analysis of randomized controlled trials”. Arch Med Sci. 2015;11(2):253–266.
170. Chung TW, Koo BS, Kim KO, et al. Salviae Miltiorrhizae BGE Radix increases rat striatal K(+)-stimulated dopamine release and activates the dopamine release with protection against hydrogen peroxide-induced injury in rat pheochromocytoma PC12 cells. Neurochem Res. 2006;31(1):109–120.
171. Wilson CWIII. Relative recovery and identification of carbonyl compounds from celery essential oil”. J Food Sci. 1970;35(6):766–768.
172. Xiong N, Huang J, Chen C, et al. Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson’s disease. Neurobiol Aging. 2012;33(8):1777–1791.
173. Zhang T, Yan W, Li Q, et al. 3-n-butylphthalide (NBP) attenuated neuronal autophagy and amyloid-beta expression in diabetic mice subjected to brain ischemia. Neurol Res. 2011;33(4):396–404.
174. Liu YW, Zhu X, Li W, et al. Ginsenoside Re attenuates diabetes-associated cognitive deficits in rats. Pharmacol Biochem Behav. 2012;101(1):93–98.
175. Yin Z, Yu H, Chen S, et al. Asiaticoside attenuates diabetes-induced cognition deficits by regulating PI3K/Akt/NF-κB pathway. Behav Brain Res. 2015;292:288–299.
176. Schmatz R, Mazzanti CM, Spanevello R, et al. Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2009;610(1–3):42–48.
177. Alrefaie Z, Alhayani A. Vitamin D₃ improves decline in cognitive function and cholinergic transmission in prefrontal cortex of streptozotocin-induced diabetic rats. Behav Brain Res. 2015;287:156–162.
178. Zhao Q, Matsumoto K, Tsuneyama K, et al. Diabetes-induced central cholinergic neuronal loss and cognitive deficit are attenuated by tacrine and a Chinese herbal prescription, kangen-karyu:elucidation in type 2 diabetes db/db mice. J Pharmacol Sci. 2011;117(4):230–242.
179. Zhong Y, Zhu Y, He T, et al. Rolipram-induced improvement of cognitive function correlates with changes in hippocampal CREB phosphorylation, BDNF and Arc protein levels. Neurosci Lett. 2016;610:171–176.
180. Fremont L. Biological effects of resveratrol. Life Sciences. 2000;66(8):663–673.
181. Alzheimer’s Disease Cooperative Study, Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85(16):1383–1391.
182. Kennedy DO, Wightman EL, Reay JL, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans:A double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr. 2010;91(6):1590–1597.
183. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127(6):1109–1122.
184. Wang L, Waltenberger B, Pferschy-Wenzig EM, et al. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ):a review. Biochem Pharmacol. 2014;92(1):73–89.
185. Rao AA. Views and opinion on BDNF as a target for diabetic cognitive dysfunction. Bioinformation. 2013;9(11):551–554.
186. Hamed SA. Cerebrolysin in treatment of acquired peripheral nervous system diseases:A clinical experience. Neural Regen Res. 2011;6(18):1415–1420.
187. Chiarelli F, Santilli F, Mohn A. Role of growth factors in the development of diabetic complications. Horm Res. 2000;53(2):53–67.
188. Serbedžija P, Ishii DN. Insulin and insulin-like growth factor prevent brain atrophy and cognitive impairment in diabetic rats. Indian J Endocrinol Metab. 2012;16(Suppl 3):S601–610.
189. Zhang D, Xiao Q, Luo H, et al. Effects of angiotensin-(1-7) on hippocampal expressions of GFAP and GDNF and cognitive function in rats with diabetes mellitus. Nan Fang Yi Ke Da Xue Xue Bao. 2015;35(5):646–651.
190. Wang CY, Li XD, Hao ZH, et al. Insulin-like growth factor-1 improves diabetic cardiomyopathy through antioxidative and anti-inflammatory processes along with modulation of Akt/GSK-3β signaling in rats. Korean J Physiol Pharmacol. 2016;20(6):613–619.
191. Enhamre-Brolin E, Carlsson A, Hallberg M, et al. Growth hormone reverses streptozotocin-induced cognitive impairments in male mice. Behav Brain Res. 2013;238:273–278.
192. Moreira PI, Rolo AP, Sena C, et al. Insulin attenuates diabetes-related mitochondrial alterations:a comparative study. Med Chem. 2006;2(3):299–308.
193. Verhagen AM, Vaux DL. Molecular mechanisms of apoptosis:an overview. Results Probl Cell Differ. 1999;23:11–24.
194. Moreira PI, Santos MS, Oliveira CR. Alzheimer’s disease:a lesson from mitochondrial dysfunction. Antioxid Redox Signal. 2007;9(10):1621–1630.
195. Moreira PI, Duarte AI, Santos MS, et al. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer’s disease. J Alzheimers Dis. 2009;16(4):741–761.
196. Price TO, Farr SA, Niehoff ML, et al. Protective effect of topiramate on hyperglycemia-induced cerebral oxidative stress, pericyte loss and learning behavior in diabetic mice. Int Libr Diabetes Metab. 2015;1(1):6–12.
197. Jayanarayanan S, Smijin S, Peeyush KT, et al. NMDA and AMPA receptor mediated excitotoxicity in cerebral cortex of streptozotocin induced diabetic rat:ameliorating effects of curcumin. Chem Biol Interact. 2013;201(1–3):39–48.
198. Newsholme P, Cruzat VF, Keane KN, et al. Molecular mechanisms of ROS production and oxidative stress in diabetes. Biochem J. 2016;473(24):4527–4550.
199. Hirose D, Hanyu H, Fukusawa R, et al. Circulating levels of advanced glycation end products in diabetes mellitus-related dementia. J Am Geriatr Soc. 2015;63(10):2196–2198.
200. Spauwen PJ, Van Eupen MG, Köhler S, et al. Associations of advanced glycation end-products with cognitive functions in individuals with and without type 2 diabetes:the maastricht study. J Clin Endocrinol Metab. 2015;100(3):951–960.
201. Lu J, Wu DM, Zheng YL, et al. Ursolic acid improves high fat diet-induced cognitive impairments by blocking endoplasmic reticulum stress and IκB kinase β/nuclear factor-κB-mediated inflammatory pathways in mice. Brain Behav Immun. 2011;25(8):1658–1667.
202. National Institute for Health and Clinical Excellence. Clinical guideline 66. Type 2 diabetes. London; 2008. Available from:https://www.nive.org.uk/guidance
203. Guyot LL, Diaz FG, O’Regan MH, et al. The effect of topical insulin on the release of excitotoxic and other amino acids from the rat cerebral cortex during streptozotocin-induced hyperglycemic ischemia. Brain Res. 2000;872(1–2):29–36.
204. Sima AA, Kamiya H. Is C-peptide replacement the missing link for successful treatment of neurological complications in type 1 diabetes? Curr Drug Targets. 2008;9(1):37–46.
205. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment:a pilot clinical trial. Arch Neurol. 2012;69(1):29–38.•• A recent finding of the neuroprotective effect of insulin on cognition.
206. Salituro GM, Pelaez F, Zhang BB. Discovery of a small molecule insulin receptor activator. Recent Prog Horm Res. 2001;56:107–126.
207. Zhang Y, Moerkens M, Ramaiahgari S, et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res. 2011;13(3):R52.
208. Hu X, Wang S, Xu J, et al. Triterpenoid saponins from Stauntonia chinensis ameliorate insulin resistance via the AMP-activated protein kinase and IR/IRS-1/PI3K/Akt pathways in insulin-resistant HepG2 cells. Int J Mol Sci. 2014;15(6):10446–10458.
209. De Felice FG1, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer’s-linked toxins:insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc Natl Acad Sci U S A. 2009;106(6):1971–1976.
210. Zhao WQ, Lacor PN, Chen H, et al. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric Aβ. J Biol Chem. 2009;284(28):18742–18753.
211. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9(9):1173–1179.
212. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.
213. Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease associated Aβ oligomers. J Clin Invest. 2012;122(4):1339–1353.
214. Han WN, Hölscher C, Yuan L, et al. Liraglutide protects against amyloid-b protein-induced impairment of spatial learning and memory in rats. Neurobiol Aging. 2013;34(2):576–588.
215. McClean PL, Parthsarathy V, Faivre E, et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’disease. J Neurosci. 2011;31(17):6587–6594.
216. Kim SJ, Han Y. Insulin inhibits AMPA-induced neuronal damage via stimulation of protein kinase B (Akt). J Neural Transm (Vienna). 2005;112(2):179–191.
217. Welsh B, Wecker L. Effects of streptozotocin-induced diabetes on acetylcholine metabolism in rat brain. Neurochem Res. 1991;16(4):453–460.
218. Sasaki-Hamada S, Tamaki K, Otsuka H, et al. A kampo formula, ameliorates hippocampal LTD and cognitive deficits in juvenile-onset diabetes rats. J Pharmacol Sci. 2014;124(2):192–200.
219. Terasawa K, Shimada Y, Kita T, et al. Choto-san in the treatment of vascular dementia:a double-blind, placebo-controlled study. Phytomedicine. 1997;4(1):15–22.
220. Suzuki T, Futami S, Igari Y, et al. A Chinese herbal medicine, choto-san, improves cognitive function and activities of daily living of patients with dementia:a double-blind, randomized, placebo-controlled study. J Am Geriatr Soc. 2005;53(12):2238–2240.
221. Murakami Y, Zhao Q, Harada K, et al. Choto-San, a Kampo formula, improves chronic cerebral hypoperfusion-induced spatial learning deficit via stimulation of muscarinic M1 receptor. Pharmacol Biochem Behav. 2005;81(3):616–625.
222. Zhao Q, Yokozawa T, Tsuneyama K, et al. Chotosan (Diaoteng San)-induced improvement of cognitive deficits in senescence-accelerated mouse (SAMP8) involves the amelioration of angiogenic/neurotrophic factors and neuroplasticity systems in the brain. Chin Med. 2011;6:33.
223. Bruehl H, Rueger M, Dziobek I, et al. Hypothalamic-pituitary-adrenal axis dysregulation and memory impairments in type 2 diabetes. J Clin Endocrinol Metab. 2007;92(7):2439–2445.
224. Hamed SA, Youssef AH, Elserogy YE, et al. Cognitive function in patients with type 2 diabetes mellitus:relationship to stress hormone (Cortisol). J Neurol and Neurosci. 2013;4(2):3. DOI:10.3823/335
225. Iliff JJ, Chen MJ, Plog BA, et al. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J Neurosci. 2014;34(49):16180–16193.
226. Iliff JJ, Lee H, Yu M, et al. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. J Clin Invest. 2013;123(3):1299–1309.
227. Jiang Q, Zhang L, Ding G, et al. Impairment of the glymphatic system after diabetes. J Cereb Blood Flow Metab. 2016 Jun 15. pii:0271678X16654702. [Epub ahead of print].
228. Solomon A, Kåreholt I, Ngandu T, et al. Serum cholesterol changes after midlife and late-life cognition twenty-oneyear follow-up study. Neurology. 2007;68(10):751–756.
229. Sparks DL, Kryscio RJ, Connor DJ, et al. Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment:results in a clinical trial cohort. Neurodegener Dis. 2010;7(1–3):183–613.
230. Van Exel E, De Craen AJ, Gussekloo J, et al. Association between high density lipoprotein and cognitive impairment in the oldest old. Ann Neurol. 2002;51(6):716–721.
231. Yaffe K, Barrett-Connor E, Lin F, et al. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59(3):378–384.
232. Japanese Elderly Diabetes Intervention Trial Study Group, Umegaki H, Iimuro S, Shinozaki T, et al. Risk factors associated with cognitive decline in the elderly with type 2 diabetes:baseline data analysis of the Japanese elderly diabetes intervention trial. Geriatr Gerontol Int. 2012;12(Suppl 1):110–116.
233. Goh DA, Dong Y, Lee WY, et al. A pilot study to examine the correlation between cognition and blood biomarkers in a Singapore Chinese male cohort with type 2 diabetes mellitus. PLoS One. 2014;9(5):e96874.
234. Xia W, Zhang B, Yang Y, et al. Poorly controlled cholesterol is associated with cognitive impairment in T2DM:a resting-state fMRI study. Lipids Health Dis. 2015;14:47.
235. Xia W, Wang S, Sun Z, et al. Altered baseline brain activity in type 2 diabetes:a resting-state fMRI study. Psychoneuroendocrinol. 2013;38(11):2493–2501.
236. Zhou H, Lu W, Shi Y, et al. Impairments in cognition and resting-state connectivity of the hippocampus in elderly subjects with type 2 diabetes. Neurosci Lett. 2010;473(1):5–10.
237. Biswal B, Zerrin Yetkin F, Haughton VM, et al. Functional connectivity in the motor cortex of resting human brain using echo‐planar mri. Magn Reson Med. 1995;34(4):537–541.
238. Chen J, Ye X, Yan T, et al. Adverse effects of bone marrow stromal cell treatment of stroke in diabetic rats. Stroke. 2011;42(12):3551–3558.
239. Chen J, Zhang ZG, Li Y, et al. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res. 2003;92(6):692–699.
240. Chen J, Li Y, Wang L, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32(4):1005–1011.
241. Li Y, Chen J, Zhang CL, et al. Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia. 2005;49(3):407–417.
242. Li Y, Chopp M. Marrow stromal cell transplantation in stroke and traumatic brain injury. Neurosci Lett. 2009;456(3):120–123.
243. Shen LH, Li Y, Chen J, et al. Intracarotid transplantation of bone marrow stromal cells increases axon-myelin remodeling after stroke. Neuroscience. 2006;137(2):393–399.
244. Zacharek A, Chen J, Cui X, et al. Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J Cereb Blood Flow Metab. 2007;27(10):1684–1691.
245. Wang CH, Cherng WJ, Yang NI, et al. Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol. 2008;28(1):54–60.
246. Chopp M, Li Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol. 2002;1(2):92–100.
247. Hu G, Riordan JF, Vallee BL. Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc Natl Acad Sci U S A. 1994;91(25):12096–12100.
248. Chiarelli F, Pomilio M, Mohn A, et al. Serum angiogenin concentrations in young patients with diabetes mellitus. Eur J Clin Invest. 2002;32(2):110–114.
249. Newcomb JD, Sanberg PR, Klasko SK, et al. Umbilical cord blood research:current and future perspectives. Cell Transplant. 2007;16(2):151–158.
250. Hurtado O, Pradillo JM, Alonso-Escolano D, et al. Neurorepair versus neuroprotection in stroke. Cerebrovasc Dis. 2006;21(Suppl 2):54–63.
251. Lo W, O’Donnell M, Tancredi D, et al. Diabetic ketoacidosis in juvenile rats is associated with reactive gliosis and activation of microglia in the hippocampus. Pediatr Diabetes. 2016;17(2):127–139.
252. Roe TF, Crawford TO, Huff KR, et al. Brain infarction in children with diabetic ketoacidosis. J Diabetes Complications. 1996;10(2):100–108.
253. Yan Y, Dempsey RJ, Flemmer A, et al. Inhibition of Na-K-Cl- cotransporter during focal cerebral ischemia decreases edema and neuronal damage. Brain Res. 2003;961(1):22–31.
254. Ding D, Moskowitz SI, Li R, et al. Acidosis induces necrosis and apoptosis of cultured hippocampal neurons. Exp Neurol. 2000;162(1):1–12.
255. Kalimo H, Olsson Y. Effects of severe hypoglycemia on the human brain. Neuropathological case reports. Acta Neurol Scand. 1980;62(6):345–356.
256. Auer RN, Hugh J, Cosgrove E, et al. Neuropathologic findings in three cases of profound hypoglycemia. Clin Neuropathol. 1989;8(2):63–68.
257. Patrick AW, Campbell IW. Fatal hypoglycaemia in insulin-treated diabetes mellitus:clinical features and neuropathological changes. Diabet Med. 1990;7(4):349–354.
258. Yamada KA, Rensing N, Izumi Y, et al. Repetitive hypoglycemia in young rats impairs hippocampal long-term potentiation. Pediatr Res. 2004;55(3):372–379.